BRIGHTPATH BIOTHERAPEUTICS CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59 JPY | 0.00% |
|
+5.36% | -32.18% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.
Calendar
2024-05-09
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -32.18% | 26.51M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 4594 Stock
- News BrightPath Biotherapeutics Co., Ltd.
- BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment
